Tolmar, Inventor and Developer of Eligard, Announces Plans to Expand Manufacturing Facilities in Colorado

Friday, May 12, 2017 General News
Email Print This Page Comment
Font : A-A+

WINDSOR, Colo. and LINCOLNSHIRE, Ill., May 12, 2017 /PRNewswire/ -- TOLMAR Inc., the innovator,

developer, and global manufacturer of ELIGARD® (leuprolide acetate for injectable suspension), has announced plans to expand manufacturing capacity for its portfolio of products.

TOLMAR, a specialty pharmaceutical company, is adding a 225,000-square-foot

manufacturing and administrative site in Windsor, CO, to its approximately 110,000-square-foot R&D and production facilities in Fort Collins, CO.

"ELIGARD is marketed in 85 countries by TOLMAR and its partners, and the global supply is manufactured here in the United States, at our Colorado facilities. We are excited to announce plans to expand our manufacturing capacity to meet the growing demand for the TOLMAR portfolio of products," said TOLMAR Pharmaceuticals CEO Susan Rodriguez.

Please visit us in Boston at the American Urological Association Meeting, Booth 2415.

About TOLMAR

TOLMAR is a fully integrated pharmaceutical company focused on the development, approval, manufacturing, and commercialization of specialty pharmaceutical products. TOLMAR Pharmaceuticals is based in Lincolnshire, Illinois, with TOLMAR global headquarters, product development, and manufacturing facilities based in Northern Colorado. TOLMAR Pharmaceuticals has the exclusive distribution rights for ELIGARD in the US and Puerto Rico. ELIGARD is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer, developed and manufactured by TOLMAR Inc. "TOLMAR" refers to TOLMAR Holding Inc. and its wholly owned operating subsidiaries, TOLMAR Inc., TOLMAR Therapeutics, Inc., and TOLMAR Pharmaceuticals, Inc. For more information about the company, please visit www.tolmar.com. Information about ELIGARD is available at http://www.eligard.com.

Important Safety Information for ELIGARD® (leuprolide acetate for injectable suspension)

ELIGARD is a medicine for managing advanced prostate cancer. It is not a cure for advanced prostate cancer.

ELIGARD should not be used by anyone who is allergic to any drug that is in the same class as ELIGARD, or anyone who is allergic to any of the ingredients in ELIGARD.

A severe and possibly life-threatening allergic reaction called anaphylaxis has been known to happen when people receive ELIGARD and other drugs in its class. Women who are pregnant or may become pregnant should not use ELIGARD. ELIGARD can cause pregnancy loss or harm an unborn baby when used by a pregnant woman.

Elevated blood sugar and an increased risk of developing diabetes have been reported in men receiving ELIGARD and other drugs in its class. Your doctor will monitor your blood sugar levels. Increased risk of heart attack, sudden death due to heart attack, and stroke also has been reported in men using drugs in ELIGARD's class. Your doctor will monitor you for heart disease. ELIGARD may also prolong the QT/QTc interval, which can cause a certain type of irregular heartbeat. Your doctor will talk to you about the risks and benefits of taking ELIGARD.

The most common injection site adverse events are temporary burning and stinging, pain, bruising, and redness. The most common systemic adverse events include mild to severe hot flashes/sweats, fatigue, weakness, muscle pain, dizziness, clamminess, testicular shrinkage, and enlarged breasts. Other adverse reactions have been reported with drugs in ELIGARD's class. These include reduced bone density and rare but serious problems involving the pituitary gland.

Please see full Prescribing Information for additional important safety information, at www.eligard.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tolmar-inventor-and-developer-of-eligard-announces-plans-to-expand-manufacturing-facilities-in-colorado-300456752.html

SOURCE TOLMAR Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook